Due to the vigorous spreading of this novel coronavirus throughout the world, there is an urgent need to find the vaccine for it. Many scientists and young medical students are engaged in the laboratories in researching the vaccine by using scraps of the previous vaccines of the cold and the flu. Others are developing the vaccine through thorough studies of the disease. It can take several years to produce such a vaccine whenever a new virus emerges, and a vaccine needs to be developed.
Many preliminary results are reported from trials, results of which suggestions by scientists were for a 10-day course of vaccine for coronavirus. A trial conducted by the National Institute of Allergy and Infectious disease (NIAID) situated in the United States has discovered a remdesivir course with their broad investigation that can expedite recovery in the body of infected COVID-19 patients. The reports are very encouraging as it raises a hope among the public. The report also states that the 10-days of remedesivir were much more effective than placebo treatment among COVID-19 patients. The recovery mortality among patients of remedesivir of 14 days was 7.1%, and in placebo treatment was 11.9%.
Remdesivir treatment has previously been used during the treatment of the Ebola virus disease. It has shown positive effects in curing Middle East Respiratory Syndrome and Severe Acute Respiratory System, as coronaviruses also cause these. This drug has been under specific observations and testing to ensure its safety after entering in the body of COVID-19 patients with fewer side effects. There are six major trials taking place for remedesivir, which includes solidarity trials under the World Health Organization (WHO), which will be used on Indian patients.
Many other clinical trials are going on for other drugs as well. We have to patiently wait for some positive reports of these trials while taking care of our safety, meanwhile.
Url source- https://indianexpress.com/article/india/large-remdesivir-clinical-trial-in-us-shows-new-promise-6424429/
